Andelyn Biosciences and Amplo Join Forces on AAV Gene Therapy

Andelyn Biosciences has announced a collaboration with Amplo Biotechnology to manufacture adeno-associated virus (AAV) gene therapies aimed at treating conditions affecting the neuromuscular junction (NMJ). This partnership is designed to enhance the scalable production of clinical-grade AAV materials using Andelyn’s innovative suspension AAV Curator platform.

Through this collaboration, the two organizations aim to streamline the production process, ensuring that it meets current good manufacturing practice (cGMP) standards. This approach will support the advancement of Amplo’s AAV gene therapy initiatives, particularly in relation to their clinical assessments focusing on efficacy and safety for upcoming studies.

Advancing Gene Therapy for NMJ Conditions

Matt Niloff, Chief Commercial Officer of Andelyn Biosciences, expressed his commitment to supporting Amplo’s mission, stating, “As a leading clinical and commercial CDMO, we are honoured to support Amplo Biotechnology’s efforts to bring hope to patients affected by debilitating NMJ diseases.” He emphasized that their Curator platform, along with comprehensive capabilities, is tailored to help partners meet critical development and clinical milestones.

Neuromuscular junction diseases can lead to significant muscle weakness, with severe cases requiring respiratory support, wheelchair use, or tube feeding. These conditions are often life-threatening and typically diagnosed in early childhood, although they can also manifest during adolescence or adulthood. The urgency of developing effective treatments for these disorders underscores the importance of the collaboration between Andelyn and Amplo.

Focus on AMP-101 and Future Developments

Headquartered in Idaho, USA, Andelyn Biosciences specializes in the characterization, development, and production of viral vectors for gene therapies. Amplo’s flagship program, known as AMP-101, is progressing toward a first-in-human study targeting Dok7 congenital myasthenic syndrome. This initiative is based on foundational research conducted at the University of Tokyo and the University of Oxford.

Previously, Amplo received support from the National Institutes of Health’s National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIH-NIAMS) for its gene therapy program AMP-201. This backing highlights the credibility and potential impact of Amplo’s research efforts in the field of gene therapy.

The collaboration between Andelyn and Amplo marks a significant step toward advancing treatments for neuromuscular junction diseases, combining expertise in manufacturing with innovative therapeutic approaches aimed at improving patients’ lives.